Ceftazidime dosage regimen in intensive care unit patients: From a population pharmacokinetic approach to clinical practice via Monte Carlo simulations

Abstract

AIM To predict the ceftazidime dosage regimen as a function of the glomerular filtration rate expressed by the modification of the diet in renal disease (MDRD), reason for admission and mechanical ventilation in intensive care unit (ICU) patients to treat Pseudomonas aeruginosa pneumonia. METHOD A published and qualified population pharmacokinetic model was used to perform Monte Carlo simulations of ceftazidime concentrations. The serum target of 40-100mgl -1 was defined based on the minimal inhibitory concentration (MIC), the European break point (EBP), the pulmonary drug diffusion and toxicity. The recommended dosage regimens were based on the maximum percentile of the patients with simulated steady state concentrations reaching the target. RESULTS Steady-state was reached at 72h whatever the MDRD. The simulations of serum concentrations generated higher percentiles of the population reaching the target after continuous administration. We recommend a 4g continuous dose after the usual 2g loading dose for patients with MDRD from 10 to 30mlmin -1, 6g for MDRD between 40 and 80mlmin -1, 8g for MDRD from 90 to 110mlmin -1, 10g for MDRD from 120 to 190mlmin -1 and 12gday -1 for patients with MDRD higher than 200mlmin -1. CONCLUSION Our study demonstrated that in ICU patients for a given MDRD, steady-state takes longer to reach in polytrauma patients than in patients with medical or post surgery reasons for admission. Continuous infusion ensures that a higher percentage of patients reaches the target than the same dose given by discontinuous administration and this only depends on MDRD. © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.